Functional drug screening assay reveals potential glioma therapeutics

Assay and Drug Development Technologies

Volumn 9, Issue 3, 2011, Pages 281-289

  Badr, Christian E ^a,b,c   Wurdinger, Thomas ^a,b,c   Tannous, Bakhos A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAUSSIA LUCIFERASE; LUCIFERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CELL VIABILITY; DRUG SCREENING; GENE TRANSFER; GLIOBLASTOMA; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEASIBILITY STUDIES; GLIOMA; HUMANS; LUMINESCENT MEASUREMENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79957632071     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0324     Document Type: Article

References (26)

1. Fan F, Wood KV: Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5:127-136. (Pubitemid 46581246)
2. Gupta PB, Onder TT, Jiang G, et al.: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-659.
3. Piccioni F, Roman BR, Fischbeck KH, Taylor JP: A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum Mol Genet 2004;13:437-446. (Pubitemid 38239795)
4. Calabrese C, Poppleton H, Kocak M, et al.: A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82. (Pubitemid 46054518)
5. Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO: Codonoptimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005;11:435-443. (Pubitemid 40277320)
6. Badr CE, Hewett JW, Breakefield XO, Tannous BA: A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2007;2:e571.
7. Wakimoto H, Kesari S, Farrell CJ, et al.: Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009;69:3472-3481.
8. Coombe DR, Nakhoul AM, Stevenson SM, Peroni SE, Sanderson CJ: Expressed luciferase viability assay (ELVA) for the measurement of cell growth and viability. J Immunol Methods 1998;215:145-150. (Pubitemid 28404867)
9. Krakstad C, Chekenya M: Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010;9:135.
10. Zhang S, Shen HM, Ong CN: Down-regulation of c-FLIP contributes to the sensitization effect of 3,3-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol Cancer Ther 2005;4:1972-1981. (Pubitemid 43056980)
11. Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-237. (Pubitemid 40315182)
12. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW: Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004;122:131-139. (Pubitemid 39470183)
13. Zhang JH, Chung TD, Oldenburg KR: A Simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73. (Pubitemid 29278954)
14. Rizzo MA, Springer GH, Granada B, Piston DW: An improved cyan fluorescent protein variant useful for FRET. Nat Biotechnol 2004;22:445-449. (Pubitemid 38451376)
15. Murdock KC, Child RG, Fabio PF, et al.: Antitumor agents. 1. 1,4-Bis [(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 1979;22:1024-1030.
16. Curtin JF, Cotter TG: Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis. Br J Cancer 2002;87:1188-1194. (Pubitemid 35418113)
17. Wang W, Kim SH, El-Deiry WS: Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A 2006;103:11003-11008. (Pubitemid 44148408)
18. Kim SS, Peng LF, Lin W, et al.: A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology 2007;132: 311-320. (Pubitemid 46108745)
19. Cheung A, Dantzig JA, Hollingworth S, et al.: A small-molecule inhibitor of skeletal muscle myosin II. Nat Cell Biol 2002;4:83-88. (Pubitemid 34071985)
20. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL: Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 2006;66:9731-9735. (Pubitemid 44623674)
21. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S: Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987;7: 725-737. (Pubitemid 17004537)
22. Wurdinger T, Badr C, Pike L, et al.: A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 2008;5:171-173. (Pubitemid 351181745)
23. Maguire CA, Deliolanis NC, Pike L, et al.: Gaussia luciferase variant for high-throughput functional screening applications. Anal Chem 2009;81:7102-7106.
24. Badr CE, Niers JM, Tjon-Kon-Fat LA, Noske DP, Wurdinger T, Tannous BA: Realtime monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol Imaging 2009;8:278-290.
25. Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R: Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta 2007;1776:32-57. (Pubitemid 47334788)
26. Prassas I, Diamandis EP: Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 2008;7:926-935.